For over a century, the pharmaceutical industry has been bound by a paradox: billions of dollars are poured into research and development every year, yet effective treatments for too many of the world's most devastating diseases remain elusive. According to the research, only less than 10% of drugs entering clinical trials ever reach the market. This staggering inefficiency underscores why, despite remarkable advances in biology and medicine, most diseases still lack adequate treatments.
"Conventional drug discovery is fundamentally constrained," says Adityo Prakash, CEO and founder of Verseon. "The industry has been searching for answers in a small pool of chemicals synthesized over the course of the last 150 years. It's no wonder progress has been slow. We decided to break that bottleneck by starting from the ground up."
That bottleneck is a numbers game. Humanity has synthesized roughly seven million distinct drug-like compounds in modern history. It sounds impressive until compared to the decillion, 10 to the power of 33, possible drug-like molecules that could be created under the rules of chemistry. "What we have tested so far is like a few grains of sand, when entire beaches remain unexplored," Prakash explains. "It's impossible to brute-force our way through all the possibilities. The lifetime of the universe would end before we got anywhere."
